Evaluating the effects of oligopin supplementation on the turnover of bone formation and antioxidant changes in postmenopausal osteopenic women: A randomized double-blind clinical trial with placebo-concurrent controls

Tehran University of Medical Sciences0 个研究点目标入组 44 人开始时间: 待定最近更新: 2020年6月15日

适应症

试验速览

暂无简介。

•Postmenopausal women;
•Aged between 50-65;
•Diagnosis of osteopenia based on Tscore ( -2.5 SD = Tscore = -1 SD)
•To have equal physical, pediatric and complementary therapies for at least three months before entrance to study

•The subjects were excluded if they had body mass index = 40 kg/m2, the occurrence of any visible side effects of the intervention,fracture report during the follow-up period, refusal to continue the trial, history of bone disorders, history of any malignancy, diabetes, kidney failure, hepatic disease, skeletal disorders, systemic inflammatory diseases, rheumatologic disorders, degenerative joint diseases, hyperthyroidism, Cushing's syndrome, history of gastrointestinal disease or bleeding, motor disabilities, untreated psychiatric illnesses such as Alzheimer's disease, Parkinson's disease, psychosis, and current smoking and alcohol intake.As for the history of the use of drugs, women receiving osteoporosis drugs (e.g. estrogen receptor-selective agonists / antagonists, bisphosphonates, PTH, and alternative HRTs), anticonvulsants (i.e. phenobarbital, phenytoin, sodium valproate), nonsteroidal anti-inflammatory drugs (i.e. naproxen, aspirin, and ibuprofen), thiazides, diuretics, glucocorticoids were not permitted to participate in this study.

发起方